+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Novel Drug Delivery Systems (NDDS) - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 492 Pages
  • July 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5140238

Global Novel Drug Delivery Systems (NDDS) Market to Reach US$28.1 Billion by the Year 2026


In recent years, the quest for delivering therapeutic agents with enhanced efficacy and minimal side effects has resulted in the proliferation of novel drug delivery systems (NDDS) in the pharmaceutical industry. NDDS refer to new approaches, technologies, formulation, and systems used for the transportation of a pharmaceutical compound inside the body for safely achieving its desired pharmacological effects. Growth in the global market is set to be primarily driven by the benefits offered by controlled-release drug delivery systems, including reduced treatment cost, lower side effects, and enhanced therapeutic efficacy. The growing adoption of controlled-release drugs as a standard treatment for various diseases, rising awareness and demand for advanced products among physicians, and increasing prescription of controlled-release products are some of the key factors that are likely to bolster the market growth in the near future. Further, presence of several in-vivo biological barriers that impacts the drug`s stability, absorption, and bioavailability are opening lucrative opportunities for the adoption of controlled-release drug delivery systems.

The adoption of controlled-release drug delivery systems is also being propelled by the rapidly growing pediatric and geriatric population, owing to high incidence of non-adherence to prescription drugs in these age-groups. Nanotechnology has come to the fore to further enhance the relevance of continuous improvisation and innovation of NDDS, especially for administering active agents. Several terminal diseases such as immunodeficiency diseases and cancers require controlled and targeted therapy with minimum side effects, and for these systems, nanocarrier-based systems deliver a better therapeutic effect at the target site. Currently, the pharmaceutical industry is preparing for widespread adoption of nanoparticles, which represents a crucial element in advanced nanotechnology-enabled delivery systems.

Amid the COVID-19 crisis, the global market for Novel Drug Delivery Systems (NDDS) estimated at US$12.7 Billion in the year 2022, is projected to reach a revised size of US$28.1 Billion by 2026, growing at a CAGR of 20.8% over the analysis period. Nanoparticles, one of the segments analyzed in the report, is projected to grow at a 20.3% CAGR to reach US$27.2 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Embolization Particles segment is readjusted to a revised 22.9% CAGR for the next 7-year period. This segment currently accounts for a 17.3% share of the global Novel Drug Delivery Systems (NDDS) market. The rising uptake of nanotechnology and its various concepts including nanocarriers in novel drug delivery mechanisms is driving growth in the Nanoparticles segment. The use of nanoparticles in delivering drugs to cancer cells with minimum damage to healthy cells is the most promising application of nanotechnology in drug delivery currently under development.

The U.S. Market is Estimated at $120.5 Million in 2022, While China is Forecast to Reach $50.7 Million by 2026


The microRNA (miRNA) market in the U.S. is estimated at US$120.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$50.7 Million by the year 2026 trailing a CAGR of 17.7% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 13% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR. The North American region dominates the global market, owing to technological advances, government support, and excellent medical reimbursement facilities. Ever-increasing clinical trials seeking to develop novel diagnostics and therapeutics, particularly in the US, is another key growth driver. Growth in the Europe market is because of increased funding towards research in countries like Germany to encourage the entry of startups in the molecular diagnostics industry, particularly in microRNA. The microRNA market in Asia Pacific is likely to gain considerable momentum due to increasing consumer awareness, rapid growth in population, supportive government policies, healthcare infrastructure modernization, and escalating foreign investments in developing nations like India and China in the regional market. The Asia Pacific region will also be driven by advances in proteomics and genomics along with increasing adoption of novel tools that help meet research goals.

Select Competitors (Total 238 Featured):

  • AstraZeneca PLC
  • Boston Scientific Corporation
  • Cospheric LLC
  • EmboMedics, Inc.
  • F. Hoffmann-La Roche AG
  • Merit Medical Systems, Inc.
  • Mo-Sci Corporation
  • Polysciences, Inc.
  • Sirtex Medical Inc.
  • Terumo Medical Corporation

What`s New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to the digital archives
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Novel Drug Delivery Systems (NDDS) - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • 2020: A Year of Disruption & Transformation
  • As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
  • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • An Insight into Pandemic Impact on Pharmaceuticals Industry
  • COVID-19 & Other Factors Shift Focus to Different Drug Delivery Approaches
  • Novel Drug Delivery Systems Gain Interest Amid the Fight Against COVID-19
  • Nanomaterial-enabled Novel Drug Delivery Systems Gain Interest in Vaccine Development
  • Novel Drug Delivery System (NDDS): A Prelude
  • Versatile Benefits of NDDS Drive Companies to Embrace the Drug Delivery Approach
  • Patient Compliance: A Key Reason Garnering Interest in NDD
  • Regulatory Process for Novel Drug Delivery Systems
  • A Look into Current Areas of Research in Drug Delivery
  • Market Outlook
  • Nanotechnology-Enabled Drug Delivery: Primary Challenges
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Nanotechnology Bolsters Demand for NDDS
  • Prospects Remain Encouraging
  • Microfluidics Mediated NDDS Set to Make Gains
  • Nanocarriers Enable Targeted Drug Delivery Systems to Improve Therapeutic Outcomes
  • Advanced Liposomes Enable Low Soluble Drugs to Achieve Targeted Delivery
  • List of Marketed Liposome-Based Clinical Products Classified by Therapeutic Areas
  • Liposomes-based Drug Delivery Systems to touch Diverse Areas of Modern Medicine
  • Dendrimers as Ideal Drug Delivery Agents
  • List of Commercially Available Dendrimeric Products by Application Area
  • High Drug Loading Capacity of PAMAM Dendrimers Bodes Well for Targeted Drug Delivery Systems
  • Oral Thin Films Enhance NDDS Domain
  • Nanotechnology-Enabled Drug Delivery Opens New Horizons to Improve Cancer Treatments
  • Rising Cancer Incidence Drives Focus onto Novel Drug Delivery Mechanisms
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Number of New Cancer Cases and Deaths (in Million) by Region for 2020
  • Global Breakdown of Total Number of Cancer Cases by Type: 2020
  • Novel Drug Delivery System Emerges as a Potential Treatment for Pediatric Brain Tumors
  • Uptrend in Gene Therapy Market Augurs Well for Market Growth
  • Global Gene Therapy Market in US$ Million: 2020, 20223 and 2024
  • Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
  • Application of Nanotechnology-based Drug Delivery Systems for CVD Treatment
  • Global Annual Medical Cost of CVD in US$ Billion (2020-2030)
  • NDD for Antimicrobial Drugs
  • List of Select Nanotechnology-based Antimicrobial Drugs in Clinical Use
  • Nanotechnology Opens New Avenues in Antiretroviral Therapy
  • Demonstrated Activity of Select Nanotechnology-Delivered Antiretroviral Therapies
  • Novel Drug Delivery System Exhibits Potential to Target HIV Reservoirs
  • Global HIV Prevalence Seeks Need for Novel Drug Delivery Systems: Number of People Living with AIDs (in Thousands) by Region for 2020
  • Novel Drug Delivery Systems for CNS Therapeutics
  • Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
  • Nanotechnology Powers Next Wave of Change for Neglected Tropical Diseases’ Treatment
  • Novel Drug Delivery Systems Hold Edge over Existing Therapies for Diabetic Retinopathy
  • Exciting Immunology Developments Involving Graphene-based Nanomaterials
  • Nanotechnology-Based Strategies for siRNA Grows in Popularity
  • Nanoemulsions Begin to Make a Mark
  • Inorganic Nanocarriers Facilitate High Payload Capacity and Co-Delivery Platforms for MDR Cancer Therapy
  • Solid Lipid Nanoparticles Provide Increased Physical Stability in Targeted Drug Delivery
  • Recent Advancements in Polymeric Drug Delivery Systems
  • Pulmonary Delivery of Nanoparticle-Based Drugs Receives Increased Interest
  • Inhalable Liposome Formulations Attract Research Interest in Pulmonary Delivery
  • SLNs in Pulmonary Delivery of Drugs
  • Other Nanocarriers in Pulmonary Delivery
  • Increasing Importance of Gold Nanoparticles in Targeted Drug Administration
  • Gold Nanoparticles Open New Avenues in Combinatorial Cancer Therapy
  • Consistent Rise in Healthcare Spending Worldwide to Drive Market Opportunities
  • World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021 and 2023
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • TABLE 2: World 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
  • TABLE 3: World Recent Past, Current & Future Analysis for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • TABLE 4: World 7-Year Perspective for Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • TABLE 5: World Recent Past, Current & Future Analysis for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • TABLE 6: World 7-Year Perspective for Embolization Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
  • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • TABLE 7: USA Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 8: USA 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
CANADA
  • TABLE 9: Canada Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 10: Canada 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
JAPAN
  • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
  • TABLE 11: Japan Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 12: Japan 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
CHINA
  • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
  • TABLE 13: China Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 14: China 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
EUROPE
  • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
  • TABLE 15: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • TABLE 16: Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
  • TABLE 17: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 18: Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
FRANCE
  • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
  • TABLE 19: France Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 20: France 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
GERMANY
  • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
  • TABLE 21: Germany Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 22: Germany 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
ITALY
  • TABLE 23: Italy Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 24: Italy 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
UNITED KINGDOM
  • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
  • TABLE 25: UK Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 26: UK 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
REST OF EUROPE
  • TABLE 27: Rest of Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 28: Rest of Europe 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
ASIA-PACIFIC
  • Novel Drug Delivery Systems (NDDS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
  • TABLE 29: Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 30: Asia-Pacific 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
REST OF WORLD
  • TABLE 31: Rest of World Recent Past, Current & Future Analysis for Novel Drug Delivery Systems (NDDS) by Segment - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • TABLE 32: Rest of World 7-Year Perspective for Novel Drug Delivery Systems (NDDS) by Segment - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2021 & 2027
IV. COMPETITION
  • Total Companies Profiled: 238

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AstraZeneca PLC
  • Boston Scientific Corporation
  • Cospheric LLC
  • EmboMedics, Inc.
  • F. Hoffmann-La Roche AG
  • Merit Medical Systems, Inc.
  • Mo-Sci Corporation
  • Polysciences, Inc.
  • Sirtex Medical Inc.
  • Terumo Medical Corporation